APOLD1
-
Official Full Name
apolipoprotein L domain containing 1 -
Overview
APOLD1 is an endothelial cell early response protein that may play a role in regulation of endothelial cell signaling;and vascular function (Regard et al., 2004 (PubMed 15102925)). -
Synonyms
APOLD1;apolipoprotein L domain containing 1;apolipoprotein L domain-containing protein 1;DKFZP434F0318;FLJ25138;Apolipoprotein L domain containing protein 1;Vascular early response gene protein;VERGE
Recombinant Proteins
- Human
- Rat
- E.coli
- Wheat Germ
- Mammalian Cell
- In Vitro Cell Free System
- In vitro E. coli expression system
- HEK293
- E.coli expression system
- His
- GST
- His&Fc&Avi
Involved Pathway
APOLD1 involved in several pathways and played different roles in them. We selected most pathways APOLD1 participated on our site, such as , which may be useful for your reference. Also, other proteins which involved in the same pathway with APOLD1 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|
Protein Function
APOLD1 has several biochemical functions, for example, . Some of the functions are cooperated with other proteins, some of the functions could acted by APOLD1 itself. We selected most functions APOLD1 had, and list some proteins which have the same functions with APOLD1. You can find most of the proteins on our site.
| Function | Related Protein |
|---|
Interacting Protein
APOLD1 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with APOLD1 here. Most of them are supplied by our site. Hope this information will be useful for your research of APOLD1.
Resources
Related Services
Related Products
References
- Tan, JTM; Prosser, HCG; et al. High- density lipoproteins augment hypoxia-induced angiogenesis via regulation of post- translational modulation of hypoxia- inducible factor 1 alpha. FASEB JOURNAL 28:206-217(2014).
- Baral, TN; Magez, S; et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. NATURE MEDICINE 12:580-584(2006).
